Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0006142 (breast cancer)
 160,383 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Estrogen receptor-negative human breast cancer is usually an aggressive, hormone independent tumour. Recent studies show that growth of these tumours could be influenced by anti-estrogens. Anti-estrogens appear to stimulate the production of Transforming Growth Factor-beta (TGF-beta) in hormone dependent as well as independent cell lines suggesting as a result inhibition of cellular proliferation of these cell lines by TGF-beta through an autocrine/paracrine mechanism.
 ...
PMID:Anti-estrogen induced synthesis of transforming growth factor-beta in breast cancer patients. 180 25

Estrogen receptor (ER) was estimated immunohistochemically in formalin-fixed and paraffin-embedded tissue from the primary breast cancer in 349 postmenopausal patients with a high risk of recurrence and compared with the results of dextran-coated charcoal assay. There was a highly significant correlation between the ER classification obtained by the two methods (p less than 10(-6)). Patients ER positive according to immunohistochemical estimate had a significantly longer disease-free survival (p less than 0.001) and survival (p less than 0.001) than ER negative patients. The DCC assay showed an advantage of ER positive patients of the same magnitude. The patients, who were followed for a median of 86 months, were a subset of 1,700 patients participating in the Danish Breast Cancer Cooperative Group's randomized trial of adjuvant tamoxifen (TAM) treatment. In the presently analyzed subset of patients there were no statistically significant difference in disease-free survival (p = 0.52) or survival (p = 0.54) between patients who received adjuvant TAM and the controls. The same was true for receptor-defined subgroups regardless if the ER receptor was estimated in paraffin-embedded tissue or by the dextran-coated charcoal method. The analyzed subset might have been too small for demonstrating a positive effect of adjuvant TAM treatment.
 ...
PMID:Estrogen receptor in primary breast cancer estimated in paraffin-embedded tissue. A study of its usefulness compared to dextran-coated charcoal assay. 195 87

Estrogen receptor-negative, 7, 12-dimethylbenz(a)anthracene (DMBA)-induced rat mammary carcinoma (TF1357) grew equally well in ovariectomized females, ovariectomized females with thyroidectomy and ovariectomized females given injections of Tamoxifen (0.1 mg/day), Medroxyprogesterone acetate (8 mg/day) or CB-154 (1 mg/day). However, the growth of TF1357 was inhibited markedly by injections of a very large amount of 17 beta-estradiol (1 mg/2 days) and also by hypophysectomy. The growth of estrogen receptor-positive, DMBA-induced rat mammary carcinoma (8K2401) was also almost completely inhibited by hypophysectomy and injections of high doses of 17 beta-estradiol, while 8K2401 grew well in castrated males. Secretory changes characterized by vacuolation in cytoplasm were observed in 8K2401 cells in castrated males with injections of high doses of estrogen but these changes were not found in 8K2401 cells in castrated males with hypophysectomy or in TF1357 cells in ovariectomized females which had had hypophysectomy or injections of high doses of estrogen. These observations suggest that hypophysectomy and/or injections of high doses of estrogen may be effective treatment for breast cancer unresponsive to ovariectomy or injections of antiestrogen drugs.
 ...
PMID:Hypophysectomy and injections of high doses of estrogens inhibit the growth of ovary-independent rat mammary carcinomas. 196 85

Brain metastasis is one of the most critical metastatic lesion on the treatment of breast cancer. We reported a case with brain metastasis from breast cancer responding to chemoendocrine therapy. The patient was 71 years old female complaining gait disturbance. Solitary brain metastasis and multiple bone metastases of breast cancer were diagnosed by CT scan and bone scintigram. Standard radical mastectomy was done. Estrogen receptor was proved to be positive in both of the tumor and metastatic lymph node. Tamoxifen and UFT were administered as chemoendocrine therapy. Complete response of brain metastasis was recognized in CT scan and gait disturbance was complete recovered two months after the treatment. She is now living well.
 ...
PMID:[A case of brain metastasis from breast cancer responding to chemoendocrine therapy]. 217 48

Sixteen cases of male breast cancer seen over a 20-year period were reviewed. The causes of cancer of the male breast are no better understood, but major alterations in hormonal environment could be a significant factor. Some clinical characteristics correspond well with the results of other series. The median age at presentation was 61.7 years. The most frequent initial symptom was a painless mass, and the incidences of nipple discharge, central tumor location, and axillary node involvement were high. Males also had a higher incidence of local advancement which was associated with a longer delay in seeking treatment and small breast tissue. The pathologic type was infiltrating ductal type in all cases except one, and all cases showed favorable nuclear grade. Estrogen receptor analysis was performed from the tumor of 2 patients. Both of them showed a high receptor level. There was no locoregional relapse in 5 patients who received adjuvant radiotherapy in contrast to the 2 relapses in 3 patients who underwent surgery alone. And three of the five patients who received radiotherapy suffered from systemic metastasis which suggested the important role of adjuvant chemotherapy as well as radiotherapy. In light of the encouraging results about adjuvant chemotherapy in the treatment for female breast cancer with axillary lymph node involvement, it would be desirable to extend this policy to male breast cancer.
 ...
PMID:Male breast cancer--a 20-year review of 16 cases at Yonsei University. 217 38

Estrogen receptor-positive (MCF7) and -negative (BT20) human breast cancer cell lines, which are frequently used for studies on cancer chemotherapy with triphenylethylene (TPE) anti-estrogens, express at least three protein kinase C subspecies. Two of them are identified as type II PKC having the beta-sequence and type III PKC having the alpha-sequence. The other one shows typical characteristics of PKC which responds to Ca2+, phosphatidylserine and diacylglycerol, but shows kinetic properties subtly different from the previously known PKC subspecies. Immunoblot analysis has shown that this enzyme does not correspond to any of the well defined subspecies with known sequence structures. All of these PKC subspecies are similarly susceptible to the TPE antiestrogens.
 ...
PMID:Protein kinase C subspecies in estrogen receptor-positive and -negative human breast cancer cell lines. 222 28

Among 879 patients treated for breast cancer between 1975 and 1984, advanced disease was found in 125 (14%). A subgroup of 34 (4%) presented with untreated locally advanced disease without demonstrable distant metastases at the time of diagnosis (stage IIIB = T4abed, NX-2,MO). During the first 5 years (1975 through 1979), 17 patients were treated primarily with sequential radiotherapy and chemotherapy (Group A). From 1980 to 1984 (Group B), the management consisted of four courses of induction multi-drug chemotherapy followed primarily by mastectomy and additional chemotherapy. The mean follow-up for the most recent group (Group B) is 48 months. Follow-up was complete. While the local disease control rate was the same for both groups (76%), the survival was remarkably different. Group A patients experienced a median survival of 15 months, and only one survived 5 years. In Group B, the median survival was 56 months with nine patients (53%) alive between 40 and 76 months, seven (41%) of whom are 5-year survivors. While the overall mortality of patients with inflammatory breast cancer was greater in both groups when compared with the group with noninflammatory disease, the survival of patients in Group B was better than in Group A for both inflammatory and noninflammatory cancers (p less than 0.01). Estrogen receptor, nodal, and menopausal status did not influence survival. These data suggest that neoadjuvant chemotherapy improves survival for patients with stage IIIB breast carcinoma and delays the establishment or progression of distant metastases. Mastectomy is an important component in the treatment of this disease.
 ...
PMID:Multimodal therapy in locally advanced breast carcinoma. 225 34

Ten year disease-free survival (DFS) results of the Naples randomized trial of adjuvant tamoxifen (TM), 30 mg per day for 2 years versus no therapy according to receptor levels, are reported. From Feb. 1, 1978, through Dec. 31, 1983, 308 pre- and postmenopausal patients with early breast cancer entered the trial. Estrogen receptor (ER) data were available on 239 (77.6%) patients, progesterone receptor (PgR) data on 194 (63.0%), and both receptor data on 181 (58.8%). ER and PgR were assayed by dextran-coated charcoal technique in a single laboratory. The effect of adjuvant TM was significantly related to ER and PgR concentration of the primary tumor. The greatest TM benefit on DFS was evident in patients with the highest levels of receptors. The interaction between the treatment effect and receptor concentration was found whether ER and PgR were considered separately or together.
Breast Cancer Res Treat 1990 Sep
PMID:Steroid hormone receptor levels and adjuvant tamoxifen in early breast cancer. Ten year results of the Naples (GUN) Study. 226 59

There are conflicting reports of seasonal changes in steroid hormone receptor levels in breast cancer tissue. Estrogen receptor and progesterone (PR) receptor levels from 1132 tumors were thus grouped according to month of initial tumor detection or month of tissue sampling/surgery. There was a significant circannual variation in the mean monthly PR receptor concentration in patients grouped according to month of tissue sampling/surgery with peak PR levels in April (late summer-early autumn) and nadir values in August and September (late winter-early spring). There was no significant cyclic variation in estrogen receptor values. A significant annual variation in tumor PR concentration was also seen when receptor levels from individual tumors were grouped according to month of initial tumor detection, with peak PR levels found in January and February. The time interval between tumor detection and biopsy/surgery was 3.3 +/- 5.3 months (mean +/- SD) which was close to the interval between the peak PR concentration expressed by month of tumor detection compared with month of tissue sampling for receptor assay. There was also a significant seasonal variation in the month of initial tumor detection, with peak detection occurring in December (summer). The close synchrony between month of maximum tumor detection and month of peak PR concentration suggests that seasonal changes in detection of breast cancer may in part relate to seasonal changes in hormone responsiveness within tumor tissue.
 ...
PMID:Seasonal change in the concentration of progesterone receptor in breast cancer. 239 59

Estrogen receptor determinations were performed on 241 cytosols from 160 breast cancer tumors, using both dextran coated charcoal method (D.C.C.) and monoclonal antibodies (Abbott's ER-EIA kit) in order to compare the two methods, and to evaluate the clinical usefulness of this new immunological simplified assay. Intra- and inter-assay reproducibility were studied during a six month period. Intra-assay of both methods were lower than 5%. Inter-assay variation coefficients of ER-EIA studied on 35 standard curves varied from 12.5% (standard: 0) to 6.7% (standard: 250 fmoles/ml). ER determination of 80 human breast cancers were performed both by EIA and Scatchard analysis. The regression curve obtained was (EIA) = 1.04 (Scatchard) + 21 fmoles/mg of proteins (r = 0.963). With 153 breast cancer cytosols whose volume was too small for multipoint Scatchard analysis, EIA results were compared to results obtained by a "near saturating" concentration of tritiated ligand (5 nM). The regression curve obtained was (EIA) = 1.34 (5nM) + 5 fmoles/mg proteins (r = 0.978). These results can be compared with those obtained between Scatchard and 5 nM: (Scatchard) = 1.29 (5nM) - 9 fmoles/mg proteins (r = 0.985). Reproducibility was studied on clinical specimens assayed at two different periods during the clinical evaluation. Regression curves obtained were (2nd assay) = 1.05 (1st assay) - 5.5 fmoles/mg proteins for EIA, and (2nd assay) = 0.96 (1st assay) + 9 fmoles/mg proteins for DCC method. EIA assay presented an high stability for protein concentrations very low, up to 0.2 mg/ml. Finally, a very good correlation was obtained between ER-EIA and DCC method, and ER-EIA seemed specially well fitted to small tumors.
 ...
PMID:[Determination of estrogen receptors in 160 breast tumors using monoclonal antibodies: comparison of Abbott's immunoenzymatic method with the carbon dextran method]. 241 70


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>